Published in Hepatitis Weekly, January 30th, 2006
"An efficacious vaccine strategy must be capable of inducing strong responses of an appropriate phenotype that are long lasting and sufficiently broad to prevent pathogen escape mechanisms. In the present study, we use anti-CD25 mAb to augment vaccine-induced immunity in mice. We demonstrate that co-formulation of antibody and poxviral- or adenoviral-vectored vaccines induces significantly increased T cell responses to a malaria antigen; prior anti-CD25 antibody administration was not required for this effect," scientists in the United Kingdom report.
"Furthermore, this vaccination approach...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.